Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases

This study is currently recruiting participants.

Verified by M.D. Anderson Cancer Center, October 2008

Sponsors and Collaborators:	M.D. Anderson Cancer Center Susan G. Komen Breast Cancer Foundation
Information provided by:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00592462

Purpose

The objective of this pilot study is to develop and evaluate a whole body MRI technique for detecting cancer metastases. The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.

Condition	Intervention
Breast Cancer	Procedure: Whole Body MRI

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer MRI Scans

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	Whole Body MRI for Detection of Cancer Metastases

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:

Develop and evaluate a whole body MRI technique for detecting cancer metastases. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	40
Study Start Date:	December 2007
Estimated Primary Completion Date:	January 2009 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
1 Breast cancer patients with a high suspicion or confirmed bone metastases.	Procedure: Whole Body MRI The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.

Show Detailed Description

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

Breast cancer patients with a high suspicion or confirmed bone metastases.

Criteria

Inclusion:

Breast cancer patients with high suspicion or confirmed bone metastases.
Patient who have undergone a clinically indicated skeletal scintigraphy within two weeks of the MRI exam.
Patients who have signed their informed consent form to undergo the study.

Exclusion:

1) Contraindication to conventional MR imaging (e.g. metal implants, pace maker, etc.).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00592462

Contacts

Contact: Jingfei Ma, PhD

713-563-2713

Locations

United States, Texas
U.T.M.D. Anderson Cancer Center	Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Jingfei Ma, PhD

Sponsors and Collaborators

M.D. Anderson Cancer Center

Susan G. Komen Breast Cancer Foundation

Investigators

Principal Investigator:

Jingfei Ma, PhD

U.T.M.D. Anderson Cancer Center

More Information

The University of Texas M.D.Anderson Cancer Center This link exits the ClinicalTrials.gov site

Responsible Party:	U.T.M.D. Anderson Cancer Center ( Jingfei Ma, PhD/Associate Professor )
Study ID Numbers:	2007-0539
Study First Received:	January 2, 2008
Last Updated:	October 3, 2008
ClinicalTrials.gov Identifier:	NCT00592462
Health Authority:	United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:

Breast Cancer
Whole Body MRI
Magnetic Resonance Imaging
Metastases

Study placed in the following topic categories:

Skin Diseases
Neoplasm Metastasis
Breast Neoplasms
Breast Diseases

Additional relevant MeSH terms:

Neoplastic Processes
Neoplasms
Pathologic Processes
Neoplasms by Site

ClinicalTrials.gov processed this record on January 16, 2009